Gene: MAPK4

5596
ERK-4|ERK4|PRKM4|p63-MAPK|p63MAPK
mitogen-activated protein kinase 4
protein-coding
18q21.1-q21.2
Ensembl:ENSG00000141639 MIM:176949 Vega:OTTHUMG00000179853 UniprotKB:P31152
NC_000018.10
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.988e-1 (AD)  4.560e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MAP3K50.823
PTPN90.802
SLC41A10.802
NTRK30.797
SERPINE20.789
WWC10.781
LRRC8A0.774
PITPNC10.77
AGFG20.766
PRKCA0.76

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.561
OR4F29-0.506
CETP-0.347
CTNNA3-0.346
GALNT6-0.315
TRPV5-0.308
CDH1-0.307
OR6C74-0.306
ZNF683-0.305
C5orf64-0.305

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
D000082AcetaminophenAcetaminophen affects the expression of MAPK4 mRNA25064622
C430898AGN 194204AGN 194204 results in decreased expression of MAPK4 protein15318936
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of MAPK4 mRNA28522335
D000638AmiodaroneAmiodarone affects the expression of MAPK4 mRNA25064622
D000643Ammonium ChlorideAmmonium Chloride affects the expression of MAPK4 mRNA16483693
D001280AtrazineAtrazine results in increased expression of MAPK4 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of MAPK4 mRNA27195522
D004958EstradiolEstradiol results in decreased expression of MAPK4 mRNA21185374
C006780bisphenol Abisphenol A affects the expression of MAPK4 mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of MAPK4 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of MAPK4 gene28505145
C018475butyraldehydebutyraldehyde results in decreased expression of MAPK4 mRNA26079696
D002087ButyratesButyrates results in decreased expression of MAPK4 mRNA14674679
D019256Cadmium Chloride[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAPK4 mRNA12634122
D002118CalciumCalcium affects the expression of MAPK4 mRNA15913539
D002746ChlorpromazineChlorpromazine affects the expression of MAPK4 mRNA25064622
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of MAPK4 gene20938992
C023600chromic oxide[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAPK4 mRNA12634122
C017133chromous chloride[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAPK4 mRNA12634122
D003300CopperCopper deficiency results in increased expression of MAPK4 mRNA26033743
D019327Copper SulfateCopper Sulfate results in increased expression of MAPK4 mRNA19789285
D016572CyclosporineCyclosporine affects the expression of MAPK4 mRNA25064622
C017160cypermethrincypermethrin results in decreased expression of MAPK4 mRNA22528246
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of MAPK4 mRNA24317228
D003907Dexamethasone[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA16054899
D003907Dexamethasone[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA]16054899
D003907DexamethasoneTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA]16054899
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of MAPK4 mRNA17361019|2126653
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of MAPK4 mRNA26924002
D004041Dietary FatsDietary Fats results in increased expression of MAPK4 mRNA25016146
D019422Dietary SucroseDietary Sucrose results in increased expression of MAPK4 mRNA26033743
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of MAPK4 mRNA25064622
D005411Flame RetardantsFlame Retardants results in decreased expression of MAPK4 mRNA27219277
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of MAPK4 gene20938992
C039281furanfuran results in increased expression of MAPK4 mRNA25539665
D055768Halogenated Diphenyl EthersHalogenated Diphenyl Ethers results in decreased expression of MAPK4 mRNA27219277
D0150561-Methyl-3-isobutylxanthine[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA16054899
D0150561-Methyl-3-isobutylxanthine[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA]16054899
D0150561-Methyl-3-isobutylxanthineTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA]16054899
C008261lead acetate[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAPK4 mRNA12634122
D008627Mercuric ChlorideMercuric Chloride results in decreased expression of MAPK4 mRNA16507785
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of MAPK4 gene20938992
D008769MethylnitronitrosoguanidineMethylnitronitrosoguanidine results in increased expression of MAPK4 mRNA12634122
C517284monomethyl phthalatemonomethyl phthalate affects the expression of MAPK4 mRNA26924002
C025589ochratoxin Aochratoxin A results in increased acetylation of MAPK4 promoter29098329
D010269ParaquatParaquat affects the expression of MAPK4 mRNA25064622
C006253pirinixic acidpirinixic acid results in increased expression of MAPK4 mRNA25270620
D010936Plant ExtractsPlant Extracts results in decreased expression of MAPK4 mRNA23557933
C005556propionaldehydepropionaldehyde results in decreased expression of MAPK4 mRNA26079696
C089730rosiglitazone[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA16054899
C089730rosiglitazone[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA]16054899
C089730rosiglitazoneTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA]16054899
C017947sodium arsenite[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAPK4 mRNA12634122
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA]16054899
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with EGF protein] results in decreased expression of MAPK4 mRNA16054899
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA]16054899
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of MAPK4 mRNA16054899
D013752TetracyclineTetracycline affects the expression of MAPK4 mRNA25064622
D013853ThioacetamideThioacetamide affects the expression of MAPK4 mRNA25064622
D014212TretinoinTretinoin results in decreased expression of MAPK4 mRNA23724009
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of MAPK4 mRNA"26743178
D014635Valproic AcidValproic Acid affects the expression of MAPK4 mRNA25064622
D014635Valproic AcidValproic Acid results in increased methylation of MAPK4 gene29154799
D014640VancomycinVancomycin results in decreased expression of MAPK4 mRNA18930951
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of MAPK4 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004674protein serine/threonine kinase activity-TAS-  
GO:0004707MAP kinase activity-IBA21873635  
GO:0005515protein binding-IPI22939624  
GO:0005524ATP binding-IEA-  
GO:0019901protein kinase binding-ISS-  
GO:0042803protein homodimerization activity-ISS-  
GO:0046982protein heterodimerization activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-IEA-  
GO:0006468protein phosphorylation-TAS7969157  
GO:0007049cell cycle-IEA-  
GO:0007166cell surface receptor signaling pathway-IBA21873635  
GO:0010468regulation of gene expression-IBA21873635  
GO:0035556intracellular signal transduction-IBA21873635  
GO:0071310cellular response to organic substance-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-ISS-  
GO:0005654nucleoplasm-TAS-  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-ISS-  
GO:0005829cytosol-TAS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5687128MAPK6/MAPK4 signalingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28592245In silico identification of potential key regulatory factors in smoking-induced lung cancer. (2017 Jun 7)El-Aarag SABMC Med Genomics